Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$83.41 -0.9%	$87.99	$73.04 ▼ $121.90	$5.33B	0.75	769,800 shs	919,766 shs
ITCI Intra-Cellular Therapies	$131.87	$130.92	$64.09 ▼ $131.98	$14.05B	0.69	1.45 million shs	N/A
SMMT Summit Therapeutics	$27.35 +8.4%	$20.36	$2.10 ▼ $33.89	$20.18B	-0.46	3.61 million shs	4.61 million shs
TEVA Teva Pharmaceutical Industries	$14.01 +5.3%	$15.33	$12.47 ▼ $22.80	$15.89B	0.72	9.93 million shs	12.07 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-0.52%	+2.00%	-5.12%	-24.81%	-3.07%
ITCI Intra-Cellular Therapies	0.00%	0.00%	+0.17%	+4.25%	+82.22%
SMMT Summit Therapeutics	+2.48%	-3.48%	+27.70%	+14.12%	+620.57%
TEVA Teva Pharmaceutical Industries	-2.24%	-2.06%	-17.77%	-39.16%	+3.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	2.5916 of 5 stars	4.3	1.0	0.0	0.0	3.3	0.8	0.6
ITCI Intra-Cellular Therapies	3.2116 of 5 stars	2.1	3.0	0.0	4.5	2.4	1.7	0.6
SMMT Summit Therapeutics	2.6661 of 5 stars	4.5	1.0	0.0	0.0	3.5	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.0596 of 5 stars	3.4	5.0	0.8	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.70	Moderate Buy	$124.95	49.80% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
SMMT Summit Therapeutics	3.00	Buy	$35.40	29.43% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	67.23% Upside

Current Analyst Ratings Breakdown

Latest BPMC, SMMT, TEVA, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
3/26/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00
3/26/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$23.00 ➝ $35.00
3/21/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/20/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$120.00 ➝ $100.00
3/18/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/17/2025	BPMC Blueprint Medicines	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$135.00
3/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/7/2025	BPMC Blueprint Medicines	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$150.00

(Data available from 4/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	10.48	N/A	N/A	$4.67 per share	17.86
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	$700K	28,822.21	N/A	N/A	$0.11 per share	248.64
TEVA Teva Pharmaceutical Industries	$16.54B	0.96	$2.77 per share	5.05	$4.75 per share	2.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$1.08	N/A	128.32	N/A	-13.19%	-77.49%	-20.84%	5/1/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.31	N/A	N/A	N/A	N/A	-85.42%	-52.66%	4/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.33	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest BPMC, SMMT, TEVA, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.44	N/A	N/A	N/A	$158.31 million	N/A
4/29/2025	Q1 2025	SMMT Summit Therapeutics	-$0.0715	N/A	N/A	N/A	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	7.22%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	88.30%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	63.91 million	61.22 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	737.68 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

BPMC, SMMT, TEVA, and ITCI Headlines

Recent News About These Companies

Teachers Retirement System of The State of Kentucky Invests $37.69 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22 at 7:07 AM | marketbeat.com

Capital International Investors Has $58.73 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22 at 5:01 AM | marketbeat.com

Beck Mack & Oliver LLC Sells 36,160 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 21 at 7:41 AM | marketbeat.com

JB Chemicals & Pharma receives USFDA approval for Bisoprolol Tablets

April 21 at 5:37 AM | business-standard.com

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

April 21 at 3:51 AM | fool.com

Gamco Investors INC. ET AL Reduces Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 20 at 4:57 AM | marketbeat.com

39,413 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by CreativeOne Wealth LLC

April 20 at 4:28 AM | marketbeat.com

Altshuler Shaham Ltd Has $4.36 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19 at 6:30 AM | marketbeat.com

Marshall Wace LLP Purchases 2,410,420 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19 at 5:53 AM | marketbeat.com

Gabelli Funds LLC Acquires 183,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19 at 5:13 AM | marketbeat.com

Raymond James Financial Inc. Buys Shares of 1,765,593 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 18, 2025 | marketbeat.com

Russell Investments Group Ltd. Has $4.51 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 18, 2025 | marketbeat.com

Affinity Asset Advisors LLC Sells 1,000,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 17, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Increased by Jump Financial LLC

April 17, 2025 | marketbeat.com

Franklin Resources Inc. Has $1.03 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 17, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded to Hold Rating by StockNews.com

April 16, 2025 | marketbeat.com

New Bill: Representative Lizzie Fletcher introduces H.R. 999: Right to Contraception Act

April 16, 2025 | quiverquant.com

Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

April 16, 2025 | marketbeat.com

Billionaire Sold Broadcom And Bought This Stock That Could Soar 121%

April 16, 2025 | 247wallst.com

Stock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

April 16, 2025 | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Menora Mivtachim Holdings LTD.'s 6th Largest Position

April 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMC, SMMT, TEVA, and ITCI Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$83.41 -0.77 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$83.34 -0.06 (-0.08%)

As of 06:17 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$27.35 +2.13 (+8.45%)

Closing price 04:00 PM Eastern

Extended Trading

$27.88 +0.52 (+1.92%)

As of 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$14.01 +0.70 (+5.26%)

Closing price 03:59 PM Eastern

Extended Trading

$14.21 +0.20 (+1.43%)

As of 07:56 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time